---
title: Vitamins lower blood homocysteine levels
nct_id: NCT06772220
phase: NA
status: RECRUITING
sponsor: Oregon Health and Science University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06772220"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06772220"
last_fetched: "2026-05-10T14:06:04.716Z"
source: "Parkinson's Pathways (curated)"
---
# Vitamins lower blood homocysteine levels

**Goal (in five words):** Vitamins lower blood homocysteine levels

**Official Title:** Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

**Trial ID:** [NCT06772220](https://clinicaltrials.gov/study/NCT06772220)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Oregon Health and Science University
- **Target Enrollment:** 150 participants
- **Start Date:** 2024-03-05
- **Completion Date:** 2025-12-31
- **Conditions:** Parkinson&Amp;#39;s Disease
- **Interventions:** Folic Acid 1 MG, Vitamin B6 25 MG, Vitamin B12
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

The goal is to lower high homocysteine that can rise with levodopa use and may contribute to vascular problems and cognitive decline in people with Parkinson's. The approach gives daily folic acid 1 mg, vitamin B6 25 mg, and vitamin B12 to help the body convert homocysteine into methionine or cysteine, thereby lowering blood homocysteine levels; these supplements are intended to be added to existing levodopa treatment and generally do not reduce levodopa's benefit when used with standard decarboxylase inhibitors like carbidopa. The study is enrolling people ages 40 to 90 with probable Parkinson's who are taking at least 300 mg of levodopa per day, have a MOCA of 15 or higher, adequate kidney function, no uncontrolled high blood pressure, are not using insulin, and can give informed consent.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide informed consent.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use

Exclusion Criteria:

\-
```

## Locations (1)

- Oregon Health & Science University (OHSU), Portland, Oregon, United States _(45.5234, -122.6762)_
  - Madeline Armendariz Sullivan — (CONTACT) — 503-501-8478 — PDResearch@ohsu.edu

## Central Contacts

- Madeline Armendariz Sullivan — (CONTACT) — 503-501-8478 — PDResearch@ohsu.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT06772220*  
*HTML version: https://parkinsonspathways.com/trial/NCT06772220*  
*Source data: https://clinicaltrials.gov/study/NCT06772220*